Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Breast cancer
  • (-) = Nortier, J.W.R.
  • (-) = Putter, H.

Search results

  • RSS Feed
(1 - 15 of 15)
Perceptions of Japanese and Dutch women with early breast cancer about monitoring their quality of life
Using a quality of life (QoL)-monitor
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer
Strong CD8+lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer
Cross-cultural comparison of breast cancer patients' Quality of Life in the Netherlands and Japan
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04)
Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01)
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients - A phase II trial
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis
Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study